ENDP - Endo International plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
11.12
-0.09 (-0.80%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close11.21
Open11.17
Bid11.06 x 1300
Ask11.12 x 900
Day's range10.95 - 11.24
52-week range5.27 - 12.54
Volume3,088,501
Avg. volume6,386,154
Market cap2.489B
Beta-0.17
PE ratio (TTM)N/A
EPS (TTM)-10.60
Earnings date6 Aug 2018 - 10 Aug 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est8.59
Trade prices are not sourced from all markets
  • What Endo International’s Valuation Trend Indicates
    Market Realist4 days ago

    What Endo International’s Valuation Trend Indicates

    Endo International’s (ENDP) U.S. Branded – Sterile Injectables segment includes branded sterile injectable products such as Vasostrict, Adrenalin, and Aplisol, and generic sterile injectable products such as ephedrine sulphate injection and neostigmine methylsulfate injection. Revenues from this segment increased from $172.17 million in Q1 2017 to $215.85 million in Q1 2018.

  • Endo’s Generic and International Segments Declined in Q1 2018
    Market Realist4 days ago

    Endo’s Generic and International Segments Declined in Q1 2018

    Under Endo International’s (ENDP) established products, Percocet sales increased from $30.94 million in Q1 2017 to $31.97 million in Q1 2018. The increase was attributable to higher prices, partially offset by a decline in volume. Voltaren gel sales, on the other hand, decreased from $14.27 million in Q1 2017 to $11.32 million in Q1 2018 due to lower prices resulting from generic competition. Sales from other established products also decreased, from $64.48 million in Q1 2017 to $45.03 million in Q1 2018.

  • Analyzing Endo International’s Financial Performance
    Market Realist4 days ago

    Analyzing Endo International’s Financial Performance

    Endo International (ENDP) generated revenues of $700.5 million in the first quarter compared to $1.04 billion in Q1 2017. Endo International incurred a cost of revenues of $403.59 million in the first quarter compared to $668.96 million in Q1 2017. Its gross profit was $296.93 million in the first quarter compared to $368.64 million in Q1 2017.

  • Endo International’s Specialty and Established Products in Q1
    Market Realist4 days ago

    Endo International’s Specialty and Established Products in Q1

    Endo International’s (ENDP) net interest expense increased from $111.9 million in Q1 2017 to $123.9 million in Q1 2018. While the company received an income tax benefit of $11.9 million in Q1 2017, it had an income tax expense of $15.49 million in Q1 2018. That led to an increase in its net loss from $173.83 million in Q1 2017 to $505.48 million in Q1 2018. That translated to a net loss per share of $2.26 in Q1 2018 compared to a net loss per share of $0.78 in Q1 2017.

  • What Analysts Think of Endo International
    Market Realist4 days ago

    What Analysts Think of Endo International

    Of the 19 analysts covering Endo International (ENDP) stock in July, four of them have given the stock a “buy” or higher rating, 14 have given it a “hold,” and one has given it a “sell.” The mean rating for the stock is 2.74 with a target price of $8.53. Sixteen of the 20 analysts covering Abbott Laboratories (ABT) in July have given the stock a “buy” or higher rating, and four have given it a “hold.” The mean rating for the stock is 1.8 with a target price of $69.

  • Is Endo International a Great Stock for Value Investors?
    Zacks13 days ago

    Is Endo International a Great Stock for Value Investors?

    Let???s see if Endo International (ENDP) stock is a good choice for value-oriented investors right now from multiple angles.

  • Is the Options Market Predicting a Spike in Endo International (ENDP) Stock?
    Zacks17 days ago

    Is the Options Market Predicting a Spike in Endo International (ENDP) Stock?

    Investors need to pay close attention to Endo International (ENDP) stock based on the movements in the options market lately.

  • Market Realistlast month

    Why Endo International Stock Rose 5.5% on June 12

    On June 11, after the markets closed, Endo International (ENDP) announced that its subsidiaries Endo Pharmaceuticals and Auxilium Pharmaceuticals have entered into a master settlement agreement. This agreement is intended to resolve all known TRT (testosterone replacement therapy) product liability claims the company faces. The company said that the agreement isn’t expected to increase Endo’s product liability reserve, as the company has already recorded an accrual for the settlement in Q4 2017.

  • CNBClast month

    Cramer's lightning round: I can't get people to buy Alibaba's stock

    Jim Cramer laments investors' distaste in the e-commerce conglomerate while taking questions in the lightning round.

  • Endo International (ENDP) Up 12.4% Since Earnings Report: Can It Continue?
    Zackslast month

    Endo International (ENDP) Up 12.4% Since Earnings Report: Can It Continue?

    Endo International (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Endo International plc (NASDAQ:ENDP): Is Breakeven Near?
    Simply Wall St.last month

    Endo International plc (NASDAQ:ENDP): Is Breakeven Near?

    Endo International plc’s (NASDAQ:ENDP): Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. With the latest financial yearRead More...

  • Why Endo International plc Rocketed Higher Today
    Motley Foollast month

    Why Endo International plc Rocketed Higher Today

    Traders take the generic-drug maker on a ride.

  • GlobeNewswirelast month

    Consolidated Research: 2018 Summary Expectations for Summit Therapeutics, Orbotech, Amphastar Pharmaceuticals, Mizuho Financial Group, Endo International plc, and AXT — Fundamental Analysis, Key Performance Indications

    NEW YORK, June 05, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Summit ...

  • Barrons.comlast month

    Valeant, Endo Both Buys in Specialty Pharma

    Deutsche Bank's Gregg Gilbert takes a look at the specialty-pharmaceutical sector on Friday, writing that Valeant Pharmaceuticals International (VRX) and Endo International (ENDP) both look poised for more gains. Gilbert reiterated a Buy rating on Valeant and raised his price target by $2 to $25, based on more upbeat estimates for irritable-bowel drug Xifaxan, currently its biggest seller at around1 13% of sales. As for Endo, Gilbert reiterated a Buy rating as well, although he did lower his price target by $2 to $10.

  • BioDelivery (BDSI) Q1 Earnings and Sales Beat Estimates
    Zacks2 months ago

    BioDelivery (BDSI) Q1 Earnings and Sales Beat Estimates

    BioDelivery Sciences' (BDSI) reports narrower-than-expected loss in Q1. Sales marginally beat the consensus mark.

  • Xiaflex & Sterile Injectables Drive Endo's (ENDP) Q1 Earnings
    Zacks2 months ago

    Xiaflex & Sterile Injectables Drive Endo's (ENDP) Q1 Earnings

    Endo's (ENDP) first-quarter results beat earnings on both counts driven by growth in Xiaflex and sterile injectables.

  • Barrons.com2 months ago

    Valeant Upside, Shire Buyout Don't Rally Pharma Stocks

    Some pharma stocks are on the rise today, following earnings and Shire's (SHPG) $62 billion takeover deal, but the goodwill didn't spread to all regions of the sector. Valeant Pharmaceuticals International (VRX) delivered a beat-and-raise first quarter, saying it earned 89 cents a share on revenue of $2 billion, while analysts expected EPS of 60 cents on revenue of $1.95 billion. For the full year, it now sees revenue of $8.15 billion to $8.35 billion, up from its previous $8.1  billion-$8.3 billion range, and above the $8.23 billion consensus estimate.

  • Is the Options Market Predicting a Spike in Endo International (ENDP) Stock?
    Zacks2 months ago

    Is the Options Market Predicting a Spike in Endo International (ENDP) Stock?

    Investors need to pay close attention to Endo International (ENDP) stock based on the movements in the options market lately.

  • MarketWatch2 months ago

    Endo shares rise 5% after Q1 profit, revenue beats

    Endo International PLC shares rose 5% in premarket trade Tuesday after the company reported first-quarter profit and revenue that came in above FactSet expectations. The company also affirmed its 2018 revenue guidance of $2.6 billion to $2.8 billion and 2018 guidance for adjusted EPS from continuing operations of $2.15 to $2.55.

  • PR Newswire2 months ago

    Endo Reports First-Quarter 2018 Financial Results

    DUBLIN , May 8, 2018 /PRNewswire/ -- First-quarter 2018 revenues of $701 million First-quarter 2018 Branded Specialty Products revenues increased 7 percent versus first-quarter 2017 to $112 million First-quarter ...

  • PR Newswire2 months ago

    Endo to Participate at the UBS Global Healthcare Conference

    DUBLIN , May 2, 2018 /PRNewswire/ --   Endo International plc (NASDAQ: ENDP) announced today that Paul Campanelli , President and CEO, will participate in a fireside chat at the UBS Global Healthcare Conference ...

  • PR Newswire3 months ago

    Collagenase Clostridium Histolyticum For The Investigational Treatment Of Cellulite To Be Featured During The Hot Topics Symposium At The Aesthetic Meeting 2018

    DUBLIN, April 27, 2018 /PRNewswire/ -- Endo International plc (ENDP) today announced the presentation of clinical data from a Phase 2b investigational study of collagenase clostridium histolyticum (CCH) for the treatment of cellulite. Dr. Lawrence Bass, a New York City-based, board-certified plastic surgeon, will present the data this afternoon during the Premier Global Hot Topics session, a highlight of The Aesthetics Meeting 2018, the annual meeting of the American Society for Aesthetic Plastic Surgery (ASAPS), held at the Marriott Marquis in New York City. "Hot Topics, one of the most popular sessions at the annual meeting, is about new and emerging technologies in aesthetic plastic surgery," said ASAPS-member Dr. Bass.

  • PR Newswire3 months ago

    Endo to Acquire Somerset Therapeutics and Business of Affiliate Wintac Limited

    DUBLIN, April 26, 2018 /PRNewswire/ -- Endo International plc (ENDP) today announced that it has reached definitive agreements to acquire Somerset Therapeutics, LLC, a New Jersey based specialty pharmaceutical company that develops and markets sterile injectable and ophthalmic drugs for the U.S. marketplace, and the business of its India based affiliate Wintac Limited, which operates as Somerset Therapeutics' contract developer and manufacturer.  Endo is paying approximately $190 million in total for Somerset Therapeutics and Wintac's business. Together, the acquisitions will secure for Endo's Par Sterile injectable business Somerset Therapeutics' commercial and pipeline products as well as Wintac's manufacturing capabilities for those products.

  • CNW Group3 months ago

    Paladin Labs Inc. Announces Launch of New Indication for XIAFLEX® (Collagenase Clostridium Histolyticum), Broadening Its Use to the Treatment of Appropriate Patients with Peyronie's Disease

    Paladin Labs Inc. Announces Launch of New Indication for XIAFLEX® (Collagenase Clostridium Histolyticum), Broadening Its Use to the Treatment of Appropriate Patients with Peyronie's Disease

  • CNW Group3 months ago

    Paladin Labs Announces the Launch of Unisom® Snore Relief, the Only Natural Health Product Throat Spray Available in Canada to Help Relieve Symptoms Associated with Snoring

    Paladin Labs Announces the Launch of Unisom® Snore Relief, the Only Natural Health Product Throat Spray Available in Canada to Help Relieve Symptoms Associated with Snoring